Get the Stockscreener App
8.2293
4.83%
0.3793
Greenwich Lifesciences Inc stock is traded at $8.2293, with a volume of 26,075.
It is up +4.83% in the last 24 hours and down -17.62% over the past month.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
See More
Previous Close:
$7.85
Open:
$7.88
24h Volume:
26,075
Relative Volume:
0.35
Market Cap:
$113.32M
Revenue:
-
Net Income/Loss:
$-8.89M
P/E Ratio:
-11.76
EPS:
-0.7
Net Cash Flow:
$-6.48M
1W Performance:
-0.13%
1M Performance:
-17.62%
6M Performance:
-16.11%
1Y Performance:
-40.97%
1-Day Range:
$7.88
$8.1796
1-Week Range:
$7.78
$8.5619
52-Week Range:
$7.78
$15.47
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Name
Greenwich Lifesciences Inc
Sector
Industry
Phone
203-434-3290
Address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
8.1796 | 108.76M | 0 | -8.89M | -6.48M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.20 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
782.39 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.20 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
908.04 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.33 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | Noble Capital Markets | Outperform |
| Sep-01-21 | Initiated | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Stock (GLSI) Latest News
Is Greenwich LifeSciences Inc. stock safe for conservative investorsRate Cut & Real-Time Volume Analysis - newser.com
Why Greenwich LifeSciences Inc. stock remains on watchlistsEarnings Risk Summary & Risk Controlled Swing Trade Alerts - newser.com
Greenwich LifeSciences Inc. stock daily chart insightsQuarterly Growth Report & Technical Pattern Recognition Alerts - newser.com
What recovery options are there for Greenwich LifeSciences Inc.July 2025 Summary & Expert Approved Momentum Trade Ideas - newser.com
(GLSI) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Can Greenwich LifeSciences Inc. stock surprise with earnings upside2025 EndofYear Setup & Expert Verified Movement Alerts - newser.com
How to interpret RSI for Greenwich LifeSciences Inc. stockMarket Growth Summary & Expert Curated Trade Ideas - newser.com
Key resistance and support levels for Greenwich LifeSciences Inc.Watch List & Community Verified Swing Trade Signals - newser.com
Published on: 2025-11-14 19:58:18 - newser.com
Published on: 2025-11-14 17:28:35 - newser.com
Greenwich LifeSciences, Inc. SEC 10-Q Report - TradingView
Published on: 2025-11-14 13:13:03 - newser.com
When is the best time to exit Greenwich LifeSciences Inc.Trade Exit Summary & AI Based Buy and Sell Signals - newser.com
What candlestick patterns are forming on Greenwich LifeSciences Inc.July 2025 Setups & Verified Swing Trading Watchlists - newser.com
Several Insiders Invested In Greenwich LifeSciences Flagging Positive News - Yahoo Finance
Is Greenwich LifeSciences Inc a good long term investmentLong-Term Growth Stocks & Small Budget Capital Growth - earlytimes.in
Published on: 2025-11-13 03:10:11 - newser.com
Greenwich LifeSciences CEO Makes Bold Stock Purchase! - TipRanks
Greenwich LifeSciences CEO and CFO Snehal Patel Acquires 10,600 Shares - TradingView
[Form 4] Greenwich LifeSciences, Inc. Insider Trading Activity - Stock Titan
Greenwich LifeSciences Inc Stock Analysis and ForecastMarket Sentiment Extremes & Watch Expert Picks Before They Rally - earlytimes.in
Published on: 2025-11-10 09:06:18 - newser.com
Published on: 2025-11-10 00:18:55 - newser.com
Published on: 2025-11-09 13:08:04 - newser.com
Published on: 2025-11-07 02:38:53 - newser.com
Greenwich Lifesciences Inc Stock (GLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Greenwich Lifesciences Inc Stock (GLSI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Patel Snehal | CEO and CFO |
Oct 31 '25 |
Buy |
9.26 |
2,300 |
21,298 |
5,572,902 |
| Patel Snehal | CEO and CFO |
Apr 25 '25 |
Buy |
9.88 |
3,600 |
35,568 |
5,570,602 |
| Patel Snehal | CEO and CFO |
Apr 17 '25 |
Buy |
8.98 |
5,400 |
48,492 |
5,567,002 |
| Patel Snehal | CEO and CFO |
Apr 07 '25 |
Buy |
9.10 |
3,600 |
32,760 |
5,561,602 |
| Patel Snehal | CEO and CFO |
Apr 04 '25 |
Buy |
8.73 |
5,500 |
48,015 |
5,558,002 |
| Patel Snehal | CEO and CFO |
Jan 10 '25 |
Buy |
12.51 |
2,500 |
31,275 |
5,552,502 |
| Patel Snehal | CEO and CFO |
Jan 07 '25 |
Buy |
13.75 |
1,800 |
24,750 |
5,550,002 |
| Patel Snehal | CEO and CFO |
Jan 06 '25 |
Buy |
13.31 |
1,100 |
14,641 |
5,548,202 |
| Patel Snehal | CEO and CFO |
Jan 03 '25 |
Buy |
12.95 |
3,400 |
44,030 |
5,547,102 |
| Patel Snehal | CEO and CFO |
Jan 02 '25 |
Buy |
11.97 |
2,000 |
23,940 |
5,543,702 |
0.50%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):